Loading
companiesCompany
Araris Biotech (Taiho)
Swiss linker-technology company (AraLinQ) acquired by Taiho for up to $1.14B; first clinical ADC ARC-02 (CD79b) dosed in June 2026.
Overview
Araris Biotech, based in Zurich, is the Swiss linker-technology company behind AraLinQ, acquired by Taiho for up to 1.14 billion dollars, and its first clinical ADC, ARC-02, was dosed in June 2026. Taiho paid 400 million dollars at closing in 2025 with up to 740 million dollars in milestones, and ARC-02, a CD79b-targeted MMAE ADC built with AraLinQ site-specific conjugation, entered phase 1 in non-Hodgkin lymphoma in June 2026 as the first AraLinQ product in humans. OnCo links it to diffuse large B-cell lymphoma, to ADCs and site-specific conjugation and linker chemistry, to Taiho, and to the idea of platform designation for ADC linker-payloads so manufacturing data carry across. Whether a cleaner linker changes clinical outcomes, or only manufacturing, is the question ARC-02 will start to answer. Taiho has its own page.
Headquarters
Zurich, CH
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2025-03 | Araris Biotech (Taiho) to Taiho Pharmaceutical (Otsuka) AraLinQ site-specific ADC linker platform and preclinical ADCs | Acquisition | $400m | up to $1.14bn | source |
Type
Website
Similar pages
- CompanySynaffix (Lonza)
Shares Platform designation for ADC linker-payloads so manufacturing data carry across, Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TreatmentFutibatinib
Shares Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors, Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer, Taiho Pharmaceutical (Otsuka).
- TermLinker (ADC)
Shares Platform designation for ADC linker-payloads so manufacturing data carry across, Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TechnologyAntibody-oligonucleotide conjugates
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TrialARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TermDrug-to-antibody ratio (DAR)
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- IdeaAn open engineering platform for academic ADCs and bispecifics
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TreatmentLuveltamab tazevibulin
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
cancers
fronts
technologies
companies
trials
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.Futibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerPhase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and LymphomasPhase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsStudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or RearrangementStudy of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities